BMS-986353 for Neuromyelitis Optica Spectrum Disorder

This trial explores a new treatment called BMS-986353 (also known as CC-97540) for individuals with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition. The researchers aim to determine if this treatment is safe and can reduce disease activity by targeting specific antibodies linked to NMOSD. Participants must have NMOSD with anti-AQP4 antibodies, remain stable on their current treatment, and not have experienced a relapse in the past year. The study involves taking BMS-986353 alongside current NMOSD therapy, with regular check-ups to monitor safety and potential benefits. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

No, you can continue your current NMOSD therapy while participating in the trial.

A previous study found BMS-986353 to be safe and well-tolerated in adults with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against AQP4. Most participants did not experience serious side effects that required stopping treatment. The study examined responses to various doses of the drug, and the results were positive regarding safety. Although further research is necessary, these early findings suggest that BMS-986353 could be a promising option for those with NMOSD.¹²³⁴⁵

Unlike the standard treatments for Neuromyelitis Optica Spectrum Disorder (NMOSD), which often include immunosuppressive therapies like rituximab or eculizumab, BMS-986353 stands out because it targets the condition in a novel way. This experimental drug is designed specifically for patients who are AQP4 antibody-positive, offering a more tailored approach. Researchers are excited about BMS-986353 because it may provide a more effective treatment by directly addressing the underlying biological mechanisms of NMOSD, potentially leading to better outcomes for patients with fewer side effects.

Research has shown that BMS-986353, also known as CC-97540, is under investigation as a potential treatment for neuromyelitis optica spectrum disorder (NMOSD). This disorder often involves harmful antibodies that mistakenly attack the body, specifically targeting AQP4. Current treatments reduce flare-ups but do not eliminate these antibodies. BMS-986353 aims to target and eliminate the cells producing these antibodies, potentially lowering disease activity. Early studies on similar treatments have been promising, with some patients showing symptom improvement. However, researchers are still gathering clear evidence of BMS-986353's effectiveness in humans. Participants in this trial who are AQP4 antibody-positive NMOSD will receive BMS-986353 to further evaluate its potential benefits.¹²³⁶⁷